MarketFriction

Marksans Pharma Ltd

NSE MARKSANS · BSE 524404 · Pharmaceuticals
₹325.60 +1.02%
NSE close2026-10-01
52 week range155.00 - 350.95
Market cap₹15,532 Cr.
P/E30.1
Microcap 250 Price band 20% Delivery 39.7%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales531586560591642682708620720754856841
Expenses417453450462495543582520576594661628
Operating Profit114133110128147139127100144161195213
OPM %21%23%20%22%23%20%18%16%20%21%23%25%
Other Income1951715-02815622203525
Interest235333366667
Depreciation182221202021232327242425
Profit before tax11411310012012514311677133151200207
Tax %26%26%23%26%22%27%22%24%26%25%25%23%
Net Profit8483788998105915899114149159
EPS in Rs1.841.841.731.962.132.312.001.292.172.503.273.47
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8937679131,0001,1341,3761,4911,8522,1772,6232,9513,172
Expenses7577228348689421,0371,2321,5131,7192,0902,3502,458
Operating Profit1364578132192340259340459533601714
OPM %15%6%9%13%17%25%17%18%21%20%20%22%
Other Income9785074259506682102
Interest1071010988911122425
Depreciation2830272327364552748399100
Profit before tax1071550104157302248338424504561691
Tax %23%24%28%23%23%21%25%21%26%24%25%
Net Profit83113680121239187265315383420521
EPS in Rs1.920.220.801.872.955.764.515.886.928.409.2211.41
Dividend Payout %21%23%6%3%3%4%6%9%9%10%10%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth13%16%17%20%
Compounded Profit Growth18%12%16%48%
Stock Price CAGR21%38%46%108%
Return on Equity17%17%16%15%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital414141414141414145454545
Reserves3264013924305025958461,1611,7002,0202,4222,978
Borrowings1011001101181003034111123244322343
Other Liabilities207180209142160236307323322372451489
Total Liabilities6767227527318029021,2281,6362,1902,6813,2403,856
Fixed Assets1662702672792703033094284867769821,044
CWIP0000001231092759
Investments0000000012710
Other Assets5104524844515335999071,2051,6941,8692,2302,753
Total Assets6767227527318029021,2281,6362,1902,6813,2403,856
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1553114502723317999237230207458
Cash from Investing Activity-33-123-21-39-13-60-45-84-259-141-49-249
Cash from Financing Activity17-58-33-21-114-1580198-69-65-71
Net Cash Flow138-150-1015-760118941762193138
Free Cash Flow118-101-141114174133531842235329
CFO/OP108%43%31%73%41%134%67%66%88%77%62%99%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8489118716478729782767580
Inventory Days107120151152215155248216192217270278
Days Payable888512954787110310291949896
Cash Conversion Cycle103124140169202163217211183199247261
Working Capital Days175977709787104121122129142149
ROCE %44%23%4%10%18%25%38%23%22%21%20%19%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters43.85%43.85%43.85%43.87%43.87%43.87%43.87%43.87%43.87%43.87%43.87%43.87%
FIIs15.07%15.55%15.57%18.59%21.31%21.95%22.19%19.89%16.92%8.13%16.76%17.47%
DIIs4.02%4.76%5.17%3.75%4.10%4.30%4.55%5.50%5.28%5.91%6.57%6.19%
Public37.06%35.81%35.40%33.77%30.70%29.88%29.37%30.74%33.93%42.08%32.78%32.46%
No. of Shareholders2,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,2792,46,635

Fundamentals

Market Cap₹ 15,532 Cr.
Current Price₹ 343
Stock P/E30.1
Book Value₹ 66.7
ROCE18.8 %
ROE15.2 %
Dividend Yield0.26 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)20%
Compounded Profit Growth (TTM)48%
Consolidated figures.
Valuation
Market capRs 14,755 Cr
Enterprise valueRs 14,109 Cr
P/E (TTM)28.55x
Price to book4.88x
Price to sales4.65x
EV / EBITDA17.29x
EV / EBIT19.72x
EV / sales4.45x
Price to cash flow32.21x
Earnings yield3.50%
Dividend yield0.28%
P/E, 3-year average21.82x
P/B, 3-year average3.26x
P/E, 5-year average17.50x
P/B, 5-year average2.63x
Profitability
Operating margin (excl. other income)20.36%
Operating margin (incl. other income)23.16%
EBITDA margin25.73%
Pre-tax margin21.77%
Net profit margin16.29%
Net margin, latest quarter18.69%
ROE15.22%
ROCE19.00%
ROA11.78%
ROE, 3-year average16.16%
ROCE, 3-year average20.01%
ROA, 3-year average12.51%
ROE, 5-year average16.85%
ROCE, 5-year average20.95%
ROA, 5-year average12.86%
ROIC (approx.)22.56%
Tax rate25.06%
Other income / net worth2.73%
Growth
Sales growth (latest year)12.51%
Profit growth (latest year)9.81%
Sales CAGR, 3 years16.80%
Sales CAGR, 5 years16.48%
Profit CAGR, 3 years16.21%
Profit CAGR, 5 years12.11%
Sales growth QoQ-1.79%
Profit growth QoQ6.10%
Sales growth YoY (latest quarter)35.62%
Profit growth YoY (latest quarter)169.50%
Per share
EPS (TTM)Rs 11.40
EPS (latest year)Rs 9.22
EPS (latest quarter)Rs 3.47
EPS, 3-year averageRs 8.18
EPS, 5-year averageRs 6.99
Book value per shareRs 66.71
Sales per shareRs 69.99
Cash flow per shareRs 10.11
Free cash flow per shareRs 7.26
Dividend per share (latest year)Rs 0.90
Dividend per share, 3-year averageRs 0.77
Dividend per share, 5-year averageRs 0.61
Dividends
Dividend payout9.76%
Dividend payout, 3-year average9.32%
Dividend payout, 5-year average8.40%
Efficiency
Asset turnover0.77x
Fixed asset turnover2.83x
Inventory turnover1.53x
Inventory days239 days
Debtor days80 days
Debtors turnover4.58x
Creditor days96 days
Cash conversion cycle261 days
Working capital days149 days
Leverage
Total debtRs 343 Cr
Cash and bankRs 990 Cr
Net debtRs -646 Cr
Debt to equity0.11x
Net debt / EBITDA-0.79x
Interest coverage28.54x
Current ratio (filing 2026-03-31)5.17x
Quick ratio (filing 2026-03-31)3.32x
Trade payables (filing 2026-03-31)Rs 337 Cr
Owners' fund to total sources78.41%
Debt to assets8.91%
Cash flow
Cash from Operating Activity (latest year)Rs 458 Cr
Cash from Investing Activity (latest year)Rs -249 Cr
Cash from Financing Activity (latest year)Rs -71 Cr
Net Cash Flow (latest year)Rs 138 Cr
Free cash flow (latest year)Rs 329 Cr
FCFE (approx.: FCF + change in debt)Rs 350 Cr
Cash from ops / profit, 5 years0.78x
Sales to cash flow6.44x
Statement figures
Net sales (TTM)Rs 3,172 Cr
Net sales (latest year)Rs 2,951 Cr
Sales (latest quarter)Rs 841 Cr
Operating profit excl. other income (latest year)Rs 601 Cr
Operating profit (latest quarter)Rs 213 Cr
Other income (TTM)Rs 102 Cr
EBITDA (TTM)Rs 816 Cr
PBDT (TTM)Rs 791 Cr
Profit before tax (TTM)Rs 691 Cr
Tax (latest year)Rs 140 Cr
Net profit (TTM)Rs 517 Cr
Net profit (latest year)Rs 418 Cr
Net profit (latest quarter)Rs 157 Cr
Depreciation (TTM)Rs 100 Cr
Depreciation (latest quarter)Rs 25 Cr
Interest (TTM)Rs 25 Cr
Cost of goods sold (latest year)Rs 1,487 Cr
Total expenditure (latest year)Rs 2,350 Cr
Total income (latest year)Rs 3,033 Cr
Share capitalRs 45 Cr
ReservesRs 2,978 Cr
Shareholders' fundsRs 3,023 Cr
Total assetsRs 3,856 Cr
Net blockRs 1,044 Cr
Capital work in progressRs 59 Cr
ReceivablesRs 645 Cr
InventoryRs 972 Cr
Other liabilitiesRs 489 Cr
Shares outstanding (crore)45.32
Ownership
Promoter holding43.87% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 28.6 is at the 69th percentile of its own 9.4-year range (median 23.0, low 8.1, high 229.4).
P/B 4.88 is at the 90th percentile (median 3.31).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodMARKSANSNifty 50Difference
1 week-3.5%-2.8% -0.7 pts
1 month+1.0%-6.8% +7.8 pts
3 months+23.1%-7.6% +30.7 pts
6 months+107.5%+0.4% +107.1 pts
1 year+92.2%-9.9% +102.1 pts
2 years+3.5%-13.6% +17.1 pts
3 years+195.9%+14.2% +181.7 pts
5 years+372.6%+27.9% +344.7 pts
22 mutual fund schemes hold about ₹562 Cr. Over three months 1 bought more and 20 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan Small Cap Fund0.33%113 -21%
UTI Small Cap Fund1.75%92 -8%
Kotak MNC Fund2.79%64 -10%
UTI Large & Mid Cap Fund0.97%63 -12%
Kotak Special Opportunities Fund3.33%57 -43%
UTI Aggressive Hybrid Fund0.57%39 -37%
UTI Healthcare Fund2.23%32 -13%
UTI Multi Cap Fund1.03%22 -48%
Motilal Oswal Nifty Microcap 250 Index Fund0.72%18 -11%
Kotak Healthcare Fund2.51%17 -15%
UTI Retirement Fund0.32%15 -15%
JM Small Cap Fund1.16%11 -21%
Old Bridge Flexi Cap Fund1.99%8 -47%
Unifi Flexi Cap Fund2.32%5 -40%
JioBlackRock Flexi Cap Fund0.09%3 -7%
Samco Small Cap Fund0.69%1 +100%
Groww Nifty Total Market Index Fund0.03%0 -8%
Bandhan BSE Healthcare Index Fund0.42%0 -8%
Angel One Nifty Total Market Index Fund0.03%0 -4%
Mirae Asset Nifty Total Market Index Fund0.03%0 -8%
Motilal Oswal BSE 1000 Index Fund0.03%0 -8%
Bandhan Nifty Total Market Index Fund0.03%0 -8%

Red flags

F-score 6 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹841 Cr +35.6% vs Jun 2025. Net profit ₹159 Cr +174.1%.
Against our estimate for Jun 2026: sales +17.2%, profit +53.5% big beat. Our estimate for Sep 2026: sales Rs 924 Cr, profit Rs 150 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-20Dividend - Re 0.90 Per Share
2025-08-01Dividend - Re 0.80 Per Share
2024-09-17Dividend - Rs 0.60 Per Share
2023-06-07Dividend - Re 0.50 Per Share
2022-08-19Annual General Meeting/Dividend - Rs 0.25 Per Share
2021-09-15 Annual General Meeting/Dividend - Rs 0.25 Per Share
2021-07-01 Extra-Ordinary General Meeting
2020-09-22 Annual General Meeting/Dividend - Rs 0.10 Per Share
2019-09-19 Annual General Meeting/Dividend - Rs 0.05 Per Share
2018-09-19 Annual General Meeting/Dividend Re 0.05 Per Share
2017-09-19 Annual General Meeting/Dividend - Re 0.05 Per Share
2016-09-22 Annual General Meeting/Dividend - Re 0.12 Per Share
2015-09-23 Annual General Meeting/ Dividend - Re 0.12/- Per Share
2014-09-18Annual General Meeting / Dividend - Re 0.10/- Per Share
2013-09-19Annual General Meeting
2012-09-20Annual General Meeting
2011-09-22Annual General Meeting
2010-09-22Annual General Meeting
2009-09-17Annual General Meeting
2008-09-23Annual General Meeting
2008-03-11Fv Split Rs.10/- To Re.1/0.1000
2007-09-19Agm
2006-09-19Agm
DateTypeWhat it says
2026-09-17General UpdatesOpening of Special Window for Re-lodgment of Transfer Requests of Physical Shares
2026-09-01Concall / analyst meetSchedule of Investors Meet
2026-08-27Shareholder meetingMarksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2...
2026-08-27Shareholder meetingProceedings of 34th Annual General Meeting held on August 27, 2026
2026-08-26General UpdatesIntimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analyt...
2026-08-20Concall / analyst meetTranscript of Investors/Analyst meet Q1 FY 27 Financial Results
2026-08-13Concall / analyst meetLink of Recording of Conference call Q1 FY 27 Financial Results
2026-08-12Press ReleaseA press release dated August 12, 2026, titled "Press Release dated 12 August 2026 on the unaudited financial results of the Company for the quarter en...
2026-08-12Investor PresentationInvestor Presentation
2026-08-12Board meeting outcomeMarksans Pharma Limited has submitted to the Exchange, the unaudited financial results for the quarter ended Jun 30, 2026.
2026-08-04UpdatesBusiness Responsibility and Sustainability Report.
2026-08-04Shareholder meetingNotice of Annual General Meeting to be held on August 27, 2026
2026-08-03Concall / analyst meetSchedule for Q1FY27 Earnings Conference Call
2026-07-20General UpdatesAcquisition of 100 percent share capital of ABCnow GmbH.
2026-07-17General UpdatesSecond 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK" Phase IV
2026-07-08Press ReleaseA press release dated July 08, 2026, titled "Marksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Comp...
2026-07-03General UpdatesGeneral Updates regarding Record Date 20 August 2026 for payment of dividend.
2026-07-03General UpdatesGeneral Updates regarding Annual General Meeting scheduled to be held on 27 August 2026.
2026-07-03Record DateRecord date for the purpose of Dividend is 20-Aug-2026.
2026-07-03Record DateRecord date for the purpose of Dividend is 20-Aug-2026.
2026-07-03Board meeting outcomeOutcome of Board Meeting held on July 03, 2026.
2026-06-26UpdatesMachine Readable Form / Legible copy of Financial Results.
2026-06-23General UpdatesSecond 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK".
2026-06-16General UpdatesUpdate on acquisition of QliniQ B.V.
2026-06-09Credit Rating- RevisionIndia Ratings and Research has revised the outlook for the Company s bank loan facilities to Positive from Stable
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Marksans Pharma Ltd?

Marksans Pharma Ltd (MARKSANS) has a market capitalisation of Rs 15,532 Cr. at the 2026-10-01 close.

What is the P/E ratio of Marksans Pharma Ltd?

Marksans Pharma Ltd trades at a P/E of 30.1 on trailing twelve-month profit, at the 2026-10-01 close.

What were Marksans Pharma Ltd's latest quarterly results?

In the Jun 2026 quarter, Marksans Pharma Ltd sales was Rs 841 Cr (+35.6% vs Jun 2025) and net profit was Rs 159 Cr.

What is the 52-week high and low of Marksans Pharma Ltd?

The 52-week high is Rs 350.95 and the 52-week low is Rs 155.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03